Nivolumab (anti-PD-1)

Catalog No.A2002        Batch: A200209

Print

Technical Data

CAS No. 946414-94-4
Formulation 100 mM Pro-Ac, 20 mM Arg, pH5.0
Isotype Human IgG4
Source CHO cells
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
Purity 99%
Protein concentration 10.84mg/ml
Endotoxin Level ＜1EU/mg

Biological Activity

Description Nivolumab (anti-PD-1) is a genetically engineered, fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. MW : 143.597 KD.
Targets
PD-1/PD-L1 interaction [2]
(Cell-free assay)		 PD-1/PD-L2 interaction [2]
(Cell-free assay)
2.52 nM 2.59 nM
In vitro

The cell binding ratio of 125I-Nivolumab and 125I-Nivolumab-DTPA to PD-1 is 13.78 ± 2.90% and 10.22 ± 2.62%, respectively. Conjugating of DTPA does not affect targeting of Nivolumab to PD-1 in vitro.[1]
In vivo

In SPECT images, lesions with high 99mTc-DTPA-nivolumab uptake and relatively clear background are shown at 6 h. Thereafter, the suspected intestinal thickening in Gd-free T1WI is observed at 2 h after the addition of Gd-DTPA-nivolumab.[1]

Protocol (Only for Reference)

Cell Assay:

  • Splenocytes were isolated from the spleens obtained from humanized PD-1 over-expressing mice following standard protocol. 125I labeled Nivolumab and Nivolumab-DTPA, respectively. To perform co-culture, 125I-Nivolumab and 125I-Nivolumab-DTPA (0.37 MBq/µg) were added to the freshly isolated splenocytes (1×106 cells) grown in 6-well plates, respectively. After incubation for 12 h at 4°C, cells were collected after rinsing three times with PBS. 125I radioactivity was determined in a gamma counter to evaluate their binding efficiency to PD-1.
Animal Study:

  • Animal Models: CRC mouse models (highly expressed human PD-1 antigen)
    Dosages: 11.1 MBq/10 μg
    Administration: i.v.
    Reference: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883027/
     

Customer Product Validation

Data from [Data independently produced by , , Clin Cancer Res, 2019, doi:10.1158/1078-0432]

Apoptosis rates of Jurkat cells co-cultured for 72 h with H1975, A549 cells or H1975 with 10 μg/mL nivolumab were analyzed by Annexin V-FITC/PI assay (Left) and quantified (Right).

Data from [Data independently produced by , , Ann Surg Oncol, 2019, 26(1):139-147]

Preliminary immunotherapy drug screening using immune checkpoint inhibitors pembrolizumab and nivolumab in LGA organoids immune-enhanced with cells from a lymph node from the same patient. Mitochondrial metabolism was assessed at (c) 24 h and (d) 96 h after administration of the immunotherapy agents. Statistical significance: **p<0.05 between tumor cell-only and immune-enhanced organoids; p<0.05 between drug treatment and control of the same group.

Selleck's Nivolumab (anti-PD-1) has been cited by 81 publications

Clinical drug screening reveals clofazimine potentiates the efficacy while reducing the toxicity of anti-PD-1 and CTLA-4 immunotherapy [ Cancer Cell, 2024, S1535-6108(24)00080-1] PubMed: 38518774
Base editing screens define the genetic landscape of cancer drug resistance mechanisms [ Nat Genet, 2024, 10.1038/s41588-024-01948-8] PubMed: 39424923
Human papillomavirus-encoded circular RNA circE7 promotes immune evasion in head and neck squamous cell carcinoma [ Nat Commun, 2024, 15(1):8609] PubMed: 39366979
Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer [ J Exp Med, 2024, 221(10)e20240152] PubMed: 39190534
Assessing personalized responses to anti-PD-1 treatment using patient-derived lung tumor-on-chip [ Cell Rep Med, 2024, S2666-3791(24)00241-6] PubMed: 38703767
Genomic and transcriptomic profiling of peripheral T cell lymphoma reveals distinct molecular and microenvironment subtypes [ Cell Rep Med, 2024, 5(2):101416] PubMed: 38350451
Patient-derived follicular lymphoma spheroids recapitulate lymph node signaling and immune profile uncovering galectin-9 as a novel immunotherapeutic target [ Blood Cancer J, 2024, 14(1):75] PubMed: 38697976
Patient-derived follicular lymphoma spheroids recapitulate lymph node signaling and immune profile uncovering galectin-9 as a novel immunotherapeutic target [ Blood Cancer J, 2024, 14(1):75] PubMed: 38697976
NKG2A+CD8+ T cells infiltration determines immunosuppressive contexture and inferior response to immunotherapy in clear cell renal cell carcinoma [ J Immunother Cancer, 2024, 12(1)e008368] PubMed: 38262706
EGFR mutations induce the suppression of CD8+ T cell and anti-PD-1 resistance via ERK1/2-p90RSK-TGF-β axis in non-small cell lung cancer [ J Transl Med, 2024, 22(1):653] PubMed: 39004699

FOR RESEARCH USE ONLY. NOT FOR USE IN HUMANS.

Specific storage and handling information for each product is indicated on the product datasheet. Most Selleck products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Short-term storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage.
We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.